Taysha Gene Therapies Files 8-K on Corporate Matters
Ticker: TSHA · Form: 8-K · Filed: Jun 3, 2025 · CIK: 1806310
Sentiment: neutral
Topics: corporate-governance, filing-update, fiscal-year-change
TL;DR
Taysha Gene Therapies filed an 8-K on June 2, 2025, covering corporate actions and financial updates.
AI Summary
Taysha Gene Therapies, Inc. filed an 8-K on June 3, 2025, reporting on matters submitted to a vote of security holders and financial statements. The filing indicates a change in the company's fiscal year end, though specific details on the vote or financial statements are not provided in this excerpt. The company is incorporated in Delaware and headquartered in Dallas, Texas.
Why It Matters
This filing signals potential changes in Taysha Gene Therapies' reporting structure and corporate governance, which could impact how investors receive financial information.
Risk Assessment
Risk Level: low — The filing is a routine corporate disclosure and does not appear to contain immediate negative news.
Key Numbers
- 001-39536 — SEC File Number (Identifies the company's filing with the SEC.)
- 84-3199512 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Taysha Gene Therapies, Inc. (company) — Registrant
- June 2, 2025 (date) — Date of earliest event reported
- June 3, 2025 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- Dallas, Texas (location) — Principal Executive Offices
- 3000 Pegasus Park Drive, Suite 1430 (address) — Principal Executive Offices
FAQ
What specific matters were submitted to a vote of security holders?
The filing indicates that matters were submitted to a vote of security holders, but the specific details of these matters are not provided in this excerpt.
What are the details of the change in Taysha Gene Therapies' fiscal year?
The filing states there is a change in fiscal year, but the specific new fiscal year end date is not detailed in this excerpt.
What financial statements are being filed?
The filing lists 'Financial Statements and Exhibits' as an item, but the specific financial statements are not detailed in this excerpt.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on June 2, 2025.
What is Taysha Gene Therapies' principal executive office address?
Taysha Gene Therapies' principal executive office is located at 3000 Pegasus Park Drive, Suite 1430, Dallas, Texas 75247.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 3, 2025 regarding Taysha Gene Therapies, Inc. (TSHA).